Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma
Sarah A. Holstein(University of Nebraska Medical Center), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Sarah Gooding(University of Oxford), Leslie Crews(University of California San Diego), Hannah Giles(University Hospitals Birmingham NHS Foundation Trust), Monica Shokeen(Washington University in St. Louis), Manisha Bhutani(Carolinas Healthcare System), Lydia Lee(CRUK Lung Cancer Centre of Excellence), Nina Shah(The University of Texas MD Anderson Cancer Center), Brian R. Shy(University of California, San Francisco), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Abdel Kareem Azab(Southwestern Medical Center), Jens Hillengaß(Roswell Park Comprehensive Cancer Center), Tom Cupedo(Erasmus MC Cancer Institute), Shari M. Kaiser(Bristol-Myers Squibb (United States)), Giada Bianchi(Brigham and Women's Hospital), Marcelo C. Pasquini(Cleveland Clinic), Fotis Asimakopoulos(University of Wisconsin–Madison), Eric L. Smith(Dana-Farber Cancer Institute), Lukas John(University of Hohenheim), Flavia Pichiorri(City Of Hope National Medical Center), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
|Hypoxia|2015|2.1k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k